

Applicants: Bruce D. Gaynor, Betty A. Diamond, Matthew D. Scharff,  
and Philippe Valadon  
Serial No.: 08/833,838  
Filed: April 10, 1997  
Page 2

Monday, July 9, 2001, is considered timely pursuant to 37 C.F.R. §1.7. Accordingly, this Amendment is being timely filed.

Please amend the above-identified application as follows:

In the Specification:

Please replace the paragraph at page 4, line 1 with the following:

Figure 3 depicts peptide inhibition of R4A (1 µg/ml) binding to calf thymus double stranded DNA by Enzyme Linked ImmunoSorbent Assay. ◊ = Asp-Trp-Glu-Tyr-Ser (SEQ ID NO:2)

In the Claims:

Please rewrite Claims 54-66 and 71-74 as follows:

54. (amended) A method for treating glomerulonephritis mediated by anti-double stranded (ds)-DNA antibodies in a subject in need of such treatment comprising administering to said subject at least one peptide which binds an anti-double stranded DNA antibody in an amount effective to treat glomerulonephritis, wherein said peptide comprises an amino acid sequence of (i) X-Gly-Trp-X-Arg-Val (SEQ ID NO:3), wherein X represents any amino acid known in the art; (ii) X-Trp-X-Tyr-His-X (SEQ ID NO:4), wherein X represents any amino acid known in the art; (iii) X<sub>1</sub>-Trp-X<sub>1</sub>-Tyr-X<sub>2</sub>